SAB Biotherapeutics

Recent Finacing

Series B

Recent Raise

$14M

SAB Biotherapeutics is a clinical-stage biopharma using its DiversitAb platform and transchromosomic cattle to produce fully human polyclonal IgG immunotherapies at scale for infectious, autoimmune and oncology indications.

Founded 2014

South Dakota, United States

51-100

Publicly Traded

sab.bio

Highlights

Focus Areas

Biotechnology

Clinical Trials

Therapeutics

Recent Investors

S

Financials

$37.4M

Total Raised

3

Funding rounds

3

Investors

Team

Upgrade to view the team

See the team members at SAB Biotherapeutics.